Improved Screening Methods for CCR5-Antagonists Use by Ultra Deep Sequencing and Quantitative Population-Based Sequencing Techniques: Analyzes of the Phase III Human Clinical Trials of Maraviroc (08-09).

通过超深测序和基于群体的定量测序技术改进 CCR5 拮抗剂筛选方法：Maraviroc III 期人体临床试验分析 (08-09)。

• 批准号: 172640
• 负责人: Harrigan Richard P
• 金额: $ 50.31万
• 依托单位: B.C. Centre for Excellence in HIV/AIDS (Vancouver)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-09-01 至 2011-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=172640&lang=en

The life-long nature of HAART and the ability of HIV to mutate rapidly have led to concerns about the determinants of treatment response and toxicity, as well as the development of drug resistance. It is important to develop novel classes of antiretrovira

HAART 的终生性质和 HIV 快速突变的能力引起了人们对治疗反应和毒性以及耐药性发展的决定因素的担忧。开发新型抗逆转录病毒药物非常重要